Navigation Links
Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
Date:9/24/2009

please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented in "Clinical Cancer Research" with respect to REOLYSIN, the Company's expectations related to the results of trials investigating delivery of REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 1Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 2Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 3Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 4Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 5Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 6Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 7Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 8Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 9Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 10Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 11Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 12Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 13Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 14Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 15Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 1Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 2Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 3Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 4Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 5Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 6Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 7Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 8Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 9Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 10SC Johnson a Best Company for Working Moms 57985 1SC Johnson a Best Company for Working Moms 57985 2SC Johnson a Best Company for Working Moms 57985 3